Erlotinib in lung cancer: Molecular and clinical predictors of outcome

Article Abstract:

Tumor-biopsy samples from participants are used to investigate whether responsiveness to erlotinib and its impact on survival are associated with expression by the tumor of epidermal growth factor receptor (EGFR) and EGFR gene amplification and mutations. Among patients with non-small-cell lung cancer who receive erlotinib, the presence of EGFR mutation may increase responsiveness to the agent, but it is not indicative of a survival benefit.

Science & research, Research, Patient outcomes, Genetic aspects, Lung cancer

---

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer

Article Abstract:

A study was conducted to determine whether adjuvant vinorelbine plus cisplatin prolongs overall survival among patients with completely resected early-stage non-small-cell lung cancer. The result showed that adjuvant vinorelbine plus cisplatin has an acceptable level of toxicity and prolongs ease-free and overall survival among patients with completely resected early-stage non-small-cell lung cancer.

United Kingdom, Drug therapy, Dosage and administration, Cisplatin, Vinorelbine

---

Erlotinib in previously treated non-small-cell lung cancer

Article Abstract:

A randomized, placebo-controlled, double-blind trial is conducted to determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival in non-small-cell lung cancer after the failure of first-line or second-line chemotherapy. The findings indicate that erlotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy.

Health aspects, Clinical trials

Similar abstracts:

• Abstracts: Health promotion in cancer treatment and prevention. Understanding the role of exercise in health promotion. Understanding the implications of adopting the Atkins' diet
• Abstracts: Facilitating practice learning through a clinical academy. What you need to know about .... abdominal aortic aneurysm
• Abstracts: Managing the pain of primary and secondary dysmenorrhoea. Improving the detection of polycystic ovary syndrome
• Abstracts: Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for profit organizations: 2000-2005
• Abstracts: Depression in the elderly - falls and pitfalls. FDA standards - good enough for government work? Torcetrapib and Atorvastatin-Should marketing drive the research agenda?

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.